Northland Securities Reiterates Corporate Rating for Motif Bio PLC (MTFB)
Other equities analysts also recently issued research reports about the stock. FinnCap reaffirmed a buy rating and set a GBX 125 ($1.58) price target on shares of Motif Bio PLC in a report on Tuesday, April 18th. Beaufort Securities reaffirmed a speculative buy rating on shares of Motif Bio PLC in a report on Wednesday, April 19th.
Motif Bio PLC (MTFB) remained flat at GBX 30.50 during midday trading on Friday. The company’s stock had a trading volume of 809,840 shares. Motif Bio PLC has a 1-year low of GBX 21.44 and a 1-year high of GBX 68.25. The firm’s market cap is GBX 59.74 million. The firm’s 50 day moving average price is GBX 32.86 and its 200-day moving average price is GBX 27.72.
About Motif Bio PLC
Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).
Receive News & Stock Ratings for Motif Bio PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio PLC and related stocks with our FREE daily email newsletter.